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ABSTRACT
CTCF is a master regulator of gene transcription and chromatin organisation with occupancy at 
thousands of DNA target sites genome-wide. While CTCF is essential for cell survival, CTCF haploinsuffi-
ciency is associated with tumour development and hypermethylation. Increasing evidence demonstrates 
CTCF as a key player in several mechanisms regulating alternative splicing (AS), however, the genome- 
wide impact of Ctcf dosage on AS has not been investigated.
We examined the effect of Ctcf haploinsufficiency on gene expression and AS in five tissues from Ctcf 
hemizygous (Ctcf+/-) mice. Reduced Ctcf levels caused distinct tissue-specific differences in gene expres-
sion and AS in all tissues. An increase in intron retention (IR) was observed in Ctcf+/- liver and kidney. In 
liver, this specifically impacted genes associated with cytoskeletal organisation, splicing and metabolism. 
Strikingly, most differentially retained introns were short, with a high GC content and enriched in Ctcf 
binding sites in their proximal upstream genomic region. This study provides new insights into the 
effects of CTCF haploinsufficiency on organ transcriptomes and the role of CTCF in AS regulation.
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CCCTC-binding factor (CTCF) is a highly conserved, multi-
valent, 11-zinc finger DNA-and RNA-binding protein, which 
occupies thousands of conserved target sites distributed across 
vertebrate genomes and co-ordinates topologically associating 
domain (TAD) formation [1–5]. Numerous studies have 
shown that CTCF regulates diverse biological functions 
including transcriptional activation and repression, insulation, 
high-order chromatin organisation, X-chromosome inactiva-
tion, pre-mRNA splicing, and DNA methylation [6,7]. CTCF 
binding occurs in a tissue-specific manner, and the binding 
sites themselves are highly conserved among different species 
[2–5,8,9]. Over 30% and 50% of all CTCF binding sites are 
located in intronic and intergenic regions, respectively [2,5,9].
The ubiquitously expressed transcription factor CTCF 
exhibits differential expression in mammalian tissues 
[8,10,11], which require specific CTCF levels for growth, 
differentiation and development [12–14]. Homozygous dele-
tion of Ctcf causes early embryonic lethality in mice [15], 
while mice harbouring a hemizygous deletion of Ctcf (Ctcf+/- 
) exhibit delayed post-natal growth and development [15,16]. 
Sustained Ctcf haploinsufficiency in mice has various patho-
physiological implications including spontaneous widespread 
tumour formation in diverse tissues as well as genome-wide 
aberrant hypermethylation [17]. Consistent with that, we have 
shown that CTCF acts as a haploinsufficient tumour 
suppressor [16,18,19]. Nevertheless, the underlying link 
between Ctcf haploinsufficiency and spontaneous tumour for-
mation remains to be fully elucidated.
Compelling evidence has linked CTCF to alternative splicing 
(AS) regulation due to its direct or indirect role in modulating 
splicing decisions via complex mechanisms including RNA 
Polymerase II (Pol II) elongation, transcriptional regulation of 
splicing factors, DNA methylation and chromatin organisation 
[20–25]. Despite its potential importance, the impact of altered 
CTCF dosage on AS has not been investigated at a global scale. 
More than 90% of human multi-exonic genes undergo AS in 
a tissue-specific manner [26,27]. While normal AS contributes to 
transcriptome and proteome diversity, aberrant AS can have 
deleterious effects leading to the development of several patho-
logical complications including cancer [28–30]. Therefore, iden-
tifying potential modulators of AS is critical to fully comprehend 
the aetiology and molecular pathophysiology of cancer.
In this study, we conducted transcriptomic analyses in Ctcf+/- 
mice to explore the impact of Ctcf haploinsufficiency in AS 
regulation in brain, kidney, liver, muscle, and spleen. We 
found that Ctcf haploinsufficiency induces changes to gene 
expression and AS that are strikingly tissue-specific. Intron 
retention (IR), for example, is highly upregulated in Ctcf hap-
loinsufficient liver and kidney compared to wildtype (WT) mice. 
Differential IR could be mediated by Ctcf binding sites located 
up- and downstream of retained introns.
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Results
Ctcf mediates tissue-specific gene expression and 
alternative splicing
Transcriptomic and proteomic studies have revealed that CTCF 
is expressed in all mammalian tissues at levels that vary by up to 
20-fold [10,11]. To assess the dosage-dependent impact of CTCF 
on gene regulation and AS, we examined a Ctcf haploinsufficient 
mouse model harbouring a hemizygous deletion of Ctcf. In this 
model, the entire coding region of one Ctcf allele is replaced with 
an expression cassette containing the pgk promoter and neomy-
cin gene (Ctcf+/pgkneo, herein referred to as Ctcf+/- for simplicity) 
(Fig. 1A, Supplementary Fig. 1). We selected five tissues from 
different body systems for which the relative CTCF expression 
between tissues is consistent for human and mouse 
(Supplementary Fig. 2), including lymphatic (spleen), nervous 
(brain), urinary (kidney), muscular (quadriceps femoris) and 
digestive (liver) systems. We isolated all five tissues from 11- 
week-old female mice comprising Ctcf+/- and WT littermates, 
and validated the reduction of Ctcf mRNA (by 36–41%) and Ctcf 
protein (the 130 kDa species by 18–59%) expression in Ctcf+/- 
mice by RT-qPCR and Western blotting, respectively 
(Supplementary Fig. 3). Interestingly, we observed Ctcf expres-
sion compensation at the protein level in all tissues except spleen, 
in which the Ctcf expression was less than 40% of WT Ctcf 
protein levels. Apart from the spleen, the increase in Ctcf expres-
sion from DNA to RNA and protein suggests that a post- 
transcriptional dosage compensation of Ctcf may have occurred 
(Fig. 1B).
We performed transcriptome analysis in all five tissues to 
examine differential gene regulation and differential AS 
between WT and Ctcf+/- mice. Ctcf transcript read counts 
assessed by RNA-seq in Ctcf+/- mice were significantly 
decreased in all tissues (33–39%) compared to WT mice 
(Fig. 2A). Differential gene expression analysis revealed that 
Ctcf haploinsufficiency exerts distinct tissue-specific effects. 
We detected at least 400 differentially expressed genes 
(DEGs) per tissue (a total of 3,746 DEGs in all tissues) 
(Supplementary Table 1). In all tissues other than liver, we 
detected an overall increase in gene expression (Fig. 2B), 
supporting Ctcf’s role as a transcriptional repressor [6].
Apart from Ctcf, only six genes (Carmil2, Gm38250, Gsto2, 
H2-Q7, Thap12 and Zcwpw1) were consistently differentially 
expressed in all five tissues (Fig. 2C). Carmil2, located adja-
cent to Ctcf at 8qD3, was upregulated in Ctcf+/- mice, which 
was also observed in a similar hemizygous Ctcf+/- mouse 
model [31]. ZCWPW1 in humans is located within a CTCF- 
mediated TAD and contains a CTCF-bound intronic enhan-
cer. A polymorphism (rs1476679) in this enhancer has been 
associated with increased disease risk in late onset- 
Alzheimer’s disease by affecting CTCF binding and chromatin 
topology [32,33]. A relationship between Ctcf and the other 
four genes has not been established yet.
Gene Ontology (GO)-based annotation enrichment analy-
sis of all the significant DEGs revealed a strong enrichment of 
tissue-specific biological processes (Supplementary Fig. 4). 
GO terms related to metabolism, immune response, and cel-
lular component organisation were commonly affected by Ctcf 
haploinsufficiency (Fig. 2D). These data confirm that 
a decrease in Ctcf dosage through haploinsufficiency can 
impact gene expression in a tissue-specific manner.
To examine the effect of Ctcf haploinsufficiency on the AS 
landscape, we analysed differential AS events in Ctcf+/- using 
rMATS [34]. We found that exon skipping (ES) is the most 
abundant form of differential AS detected in all tissues 
(Supplementary Table 2). Notably, we observed a significant 
increase in IR events in the liver and kidney of Ctcf+/- mice 
(Fig. 2E), which is in contrast to all other forms of AS. 
However, a decrease in Ctcf-mediated IR events was only 
detected in Ctcf+/- muscle. Overall, our analysis shows that 
Ctcf haploinsufficiency not only affects gene expression but 
also perturbs the AS landscape in a tissue-specific manner.
Characterisation of intron retention in Ctcf+/- liver
To confirm that Ctcf haploinsufficiency modulates IR in 
a tissue-specific manner, we used IRFinder, a software 








































Figure 1. Ctcf haploinsufficiency as a model to study Ctcf-mediated transcrip-
tome changes.
(A) Schematic illustration of the study design highlighting the mouse model, 
selected organs and types of data analyses. The RNA-seq data analyses per-
formed in this study were differential gene expression (DGE) and differential 
alternative splicing (DAS) including exon sipping (ES), mutually exclusive exon 
(MXE), alternative 3′ splice site (A3SS), alternative 5′ splice site (A5SS) and intron 
retention (IR). (B) Summary of Ctcf mRNA and protein expression in all five 
tissues from WT and Ctcf+/- mice (see Supplementary Fig. 3 for specific data and 
statistical analysis). The bars represent the mean ± SEM. The dashed line 
represents the expected level of Ctcf in the Ctcf haploinsufficient mice (50%). 
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Figure 2. Differential gene expression and alternative splicing in Ctcf+/- mice.
(A) Ctcf mRNA expression from five tissues as normalised read counts. The bars represent the mean ± SEM. Wald test within DESeq2 was used to determine 
significance denoted by ** (p < 0.01), *** (p < 0.001), **** (p < 0.0001). (B) Waterfall plots showing the log2 (fold changes) of all significant DEGs (p < 0.05, 
Wald test using DESeq2) in each tissue. Each vertical bar represents a single DEG which is coloured based on the p-value. The total numbers of downregulated 
(left) and upregulated (right) genes are indicated on top of each plot. The central vertical line is drawn at half of the total number of DEGs while the red 
vertical line indicates the ‘0ʹ inflection point. Liver was the only tissue not exhibiting a reduction in overall gene expression. (C) Venn diagram illustrating the 
overlap of DEGs among the five tissues. Arrows next to the common genes represent the change in their expression as up- or downregulated in all the five 
tissues. (D) Enriched functional annotations associated with DEGs common in at least four out of five tissues. Number of DEGs associated with each GO term is 
indicated within each circle. (E) Bar charts showing the number of significant differential AS events (FDR < 0.05, BH) detected in WT and Ctcf+/- tissues. Ctcf+/- 
liver exhibited a striking increase in IR. ES – exon skipping; MXE – mutually exclusive exon; A3SS – alternative 3′ splice site, A5SS – alternative 5′ splice site; IR 
– intron retention. 
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package specifically developed for the detection and quantifi-
cation of IR [35–37]. We confirmed that IR is increased in 
Ctcf+/- liver and kidney with a total of 60 and 43 upregulated 
IR events, respectively. Only 1 and 5 IR events were down-
regulated in Ctcf+/- liver and kidney, respectively (Fig. 3A, 
Supplementary Table 3). Moreover, we detected that in 
some mRNA transcripts (5 in liver and 1 in kidney) multiple 
introns were differentially retained in the same transcript. 
There were no differential IR events common to all tissues.
As Ctcf haploinsufficient liver exhibited the most dramatic 
upregulation of IR, we explored these IR events for further 
validation and characterisation. First, we calculated the IR- 
ratio for all IR events (Supplementary Fig. 5A). The IR-ratio 
is the proportion of intron-retaining mRNA transcripts com-
pared to all mRNA transcripts from the same gene. Consistent 
with previous studies, we considered IR events with an IR- 
ratio ≥0.1 as biologically significant [35,38]. Since we pre-
viously showed that IR can reduce the expression of the host 
gene via nonsense-mediated decay (NMD) [36], we examined 
the intronic expression as well as expression of host mRNA. 
We observed that 65% of differential intron-retaining genes, 
whether up- or downregulated, exhibited increased gene 
expression (Supplementary Fig. 5B). This suggests that Ctcf 
haploinsufficiency triggers both the upregulation of expres-
sion and IR-ratios of intron-retaining genes in liver.
Next, we selected five candidates exhibiting increased IR, 
including Gadd45g, Plk3, Rfx5, Ppox and Setd4 (Fig. 3B), for 
validation by RT-qPCR. We confirmed a significant increase 
in retained introns in all five genes (Fig. 3C); however, the 
impact on host mRNA expression varied (Fig. 3D). We have 
recently summarised all possible fates of intron-retaining 
transcripts [39,40]. Apart from their degradation via NMD, 
fates include the nuclear detention of intron-retaining tran-
scripts, the synthesis of novel protein isoforms, or their cel-
lular translocation. To characterise the liver-specific intron- 
retaining genes, we performed annotation enrichment analysis 
and found that the affected genes are associated with biologi-
cal processes and pathways related to metabolism, cytoskeletal 
organisation, RNA splicing and mRNA processing (Fig. 3E). 
These findings show that Ctcf haploinsufficiency mediates IR 
of specific introns in liver genes involved in splicing- and 
metabolism-related processes. In addition, we found 
a significant association between Ctcf+/–-regulated DEGs and 
IR (p-value = 0.01, Fisher’s exact test).
We next examined the molecular features of significantly 
differential IR events (n = 60) identified in Ctcf+/- liver com-
pared to expressed non-retained introns (n = 1,160) and 
found that differentially retained introns are shorter 
(p-value = 3.3e-6, Fig. 3F) and have a higher GC content 
than non-retained introns (p-value = 7.7e-12, Fig. 3G), 
which is consistent with our previous reports [36,38,41]. To 
examine whether there is a correlation between these features 
and Ctcf+/– -mediated IR, we divided differentially retained 
introns and expressed non-retained introns, based on cut-off 
values of the median length (431 nt) and the mean GC 
content (45%) of all introns, into four groups: (i) short/GC- 
rich, (ii) short/GC-poor, (iii) long/GC-rich, (iv), and long/ 
GC-poor (Supplementary Fig. 6 and Table 4). Interestingly, 
we found that 35 out of 60 (58.3%) differentially retained 
introns fall into the ‘short/GC-rich’ category, which constitu-
tes 9% of all expressed short/GC-rich introns (p-value 2.5e-5, 
Fisher’s exact test).
Enrichment of Ctcf binding sites proximal to differentially 
retained introns
CTCF ChIP-seq studies have found that approximately 30% 
and 50% of CTCF binding sites are located in intronic and 
intergenic regions, respectively [2,5,9]. It has been shown that 
the intragenic localisation of CTCF binding sites influences 
pre-mRNA splicing decisions leading to alternative exon 
inclusion [20,21,25]. To determine whether Ctcf binding 
sites are enriched in the proximity of differentially retained 
introns in liver, we analysed a publicly available ChIP-seq 
dataset from C57BL/6 normal mouse liver (E-MTAB-5769) 
[42]. Knowing that regions containing CTCF binding sites are 
mostly characterised by high GC content [5,43], we propose 
that GC-rich introns proximal to these regions are predis-
posed to IR particularly if they are short. Since short/GC-rich 
introns constitute more than half of the Ctcf-mediated differ-
entially retained introns (35 out of 60), we merged the other 
classes (i.e. short/GC-poor, long/GC-rich, and long/GC-poor) 
of differentially retained introns into one group (named: 
other).
We examined Ctcf binding sites within the intron bodies as 
well as 200–50,000 nt upstream/downstream of differentially 
retained and expressed non-retained introns. The highest fold 
increase in Ctcf binding sites was observed upstream of dif-
ferentially retained short/GC-rich introns (Fig. 4A). However, 
all differentially retained introns have a 2-fold increase in Ctcf 
binding sites in their ≤3,000 nt upstream region. These bind-
ing sites (n = 32) are primarily located in introns (50%), 
followed by intergenic regions (31.25%), and exons (18.75%, 
Fig. 4A). In the intron bodies, we observed a significantly 
higher percentage of the differentially retained short/GC-rich 
introns harbouring Ctcf binding sites compared to non- 
retained introns (11% vs. 4%, respectively, p-value = 0.02, 
Fisher’s exact test). However, the total number of introns 
harbouring Ctcf binding sites (retained: 9 short/GC-rich and 
0 others; non-retained: 23 short/GC-rich and 107 others) was 
low. Overall, these findings suggest that the Ctcf haploinsuffi-
ciency-induced IR changes in liver mostly affect short, GC- 
rich introns with proximal Ctcf binding sites. We then com-
pared our results from liver to ChIP-seq data from brain, 
kidney and spleen (GSE36027) but found no enrichment of 
IR-associated Ctcf binding sites in these data, suggesting that 
IR in Ctcf+/- liver is indeed regulated by Ctcf (Supplementary 
Fig. 7).
Since CTCF is known for its global role in transcriptional 
regulation and insulation [6], we wanted to determine 
whether manipulating Ctcf expression in vivo perturbs spli-
cing factor expression. By assessing 371 splicing factors (i.e. 
genes annotated with the GO term ‘RNA splicing’; 
GO:0008380), we detected only minor changes in the expres-
sion of splicing factors (Supplementary Fig. 8A). Interestingly, 
we found that in Ctcf+/- liver a larger number of splicing 
factors, including Srsf1, Prpf40b, Thoc1, Khsrp and Zpr1, 
exhibit retained introns (Supplementary Fig. 8B). Given the 
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Figure 3. Validation and features of differentially retained introns in liver.
(A) Volcano plots showing differentially retained introns in mouse tissues. Significant differential IR events (p < 0.05, Wald test using IRFinder and DESeq2) are 
coloured in red. The numbers on top represent introns with downregulated (top-left) and upregulated (top-right) IR and the number of significantly differentially 
retained introns in parentheses. (B) Coverage plots of five differentially retained introns selected for validation. The IR-ratio (ψ) of each retained intron is indicated 
inside the red box. (C) Bar charts showing the expression of the same five selected differentially retained introns normalised to the expression of their flanking exons. 
Unpaired two-tailed Student’s t-test was used to determine significance denoted by ns (not significant), * (p < 0.05), ** (p < 0.01), *** (p < 0.001), **** (p < 0.0001). 
(D) Bar charts showing the relative expression of the same five genes harbouring the selected differentially retained introns. (E) Enriched functional annotations 
associated with genes of the 60 significantly differentially retained introns in Ctcf+/- liver. The dashed vertical red line represents p-value = 0.05. In parentheses is the 
number of genes associated with each GO term, where only GO terms with gene number >2 were included. (F) Density plot showing distribution of intron lengths of 
differentially retained introns and expressed non-retained introns in Ctcf+/- liver. Out-of-bounds intron length values (> 2000 bp) were re-scaled and plotted at the 
maximum value. Significance is denoted by **** (p-value < 0.0001, t-test). (G) Box plot comparing the GC content between differentially retained and expressed non- 
retained introns in Ctcf+/- liver. 
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fact that IR coupled with NMD can reduce protein synthesis 
[36], our data suggest that Ctcf haploinsufficiency may drive 
IR-mediated regulation of splicing factor expression. While 
the fate and role of these dysregulated splicing factors remain 
to be determined, it would be reasonable to assume that they 
may contribute to increased IR in liver.
Figure 4. Enrichment of Ctcf binding sites proximal to differentially retained introns.
(A) Ctcf binding sites upstream (left panel), downstream (right panel), and within the body (middle panel) of differentially retained and expressed non-retained 
introns. The line graphs (left/right) show the distance-dependent fold difference in Ctcf peaks near short/GC-rich (solid line) and other (dashed line) differentially 
retained and expressed non-retained introns. The stacked bar on top of the line graph (left panel) shows the preferential genomic region of the enriched Ctcf binding 
sites of the area highlighted in grey. The insets show the cumulative number of Ctcf peaks with increasing distance from all the differentially retained (orange) and 
non-retained introns (grey). Data points represent 1,000 iterations of x (where x = number of retained introns in the relevant group) randomly selected non-retained 
introns with varying distance to the splice sites. The stacked bar graph in the middle shows the percentage (y-axis) of introns harbouring Ctcf binding sites. 
Significance is denoted by * (p-value < 0.05, Fisher’s exact test; ns – not significant). (B) Proposed model of CTCF haploinsufficiency-mediated IR changes. In contrast 
to the normal situation (green box) where splicing proceeds constitutively, in the CTCF haploinsufficient liver (red box) various factors (e.g. RNA Pol II elongation rate, 
CTCF expression, CTCF binding proximal to splice sites and the methylation status of these CTCF binding sites) contribute to increased IR. Black circles indicate 
methylated sites altered by CTCF haploinsufficiency. 
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Discussion
IR is a widespread and conserved mechanism of post- 
transcriptional gene expression regulation affecting over 80% 
of all protein coding genes [35]. For instance, we have pre-
viously shown that IR regulates differentiation across diverse 
haematopoietic lineages [36,38,41,44]. Moreover, the majority 
of cancer types have abundant IR events that affect their 
transcriptomes, including genes involved in RNA splicing 
[45,46]. Therefore, identifying the potential modulators of 
AS, particularly IR, is essential to fully comprehend the aetiol-
ogy and molecular pathophysiology of cancer.
Here, we demonstrate that Ctcf haploinsufficiency, which 
has previously been shown to induce spontaneous tumour 
formation in mice and genome-wide hypermethylation [17], 
also perturbs the AS landscape. Upon examining a number of 
tissues, we observed a specific increase of IR in Ctcf+/- liver 
and kidney. Moreover, we observed a similar tissue-specific 
effect of Ctcf haploinsufficiency on gene expression. Given 
that CTCF expression and DNA occupancy are variables 
between tissues [2–5,8,9], these differences may govern how 
CTCF specifically regulates the transcriptome and AS in 
tissues.
While the impact of CTCF haploinsufficiency on the global 
AS landscape has not been previously investigated, we utilised 
this model to examine in vivo the global effect of Ctcf dose- 
dependent regulation on AS in specific tissues. Although we 
used Ctcf hemizygous mice, we and others have shown that 
any sustained decrease in CTCF expression is partially com-
pensated at the protein levels [17,31]. However, with a less 
than 50% reduction (except spleen) of Ctcf mRNA and pro-
tein expression, we observed tissue-specific differences in gene 
expression and AS. These data suggest that more prominent 
effects might be observed with loss-of-function mutations or 
the inactivation of CTCF, which are commonly observed in 
cancer [7,47], or at an even lower CTCF dosage. However, we 
have previously shown that the enforced genetic ablation of 
CTCF has a negative impact on somatic cell viability [16].
Although the exact mechanism underlying Ctcf haploin-
sufficiency-mediated IR regulation remains to be charac-
terised, several possibilities can be proposed based on our 
data and previous studies. An optimal RNA Pol II elongation 
rate is essential for constitutive splicing [48]; therefore, both 
slow and fast RNA Pol II elongation rates were observed to 
promote IR [49]. Slowing RNA Pol II elongation mediated by 
CTCF promoted exon inclusion in B-lymphoma cell lines, 
providing the first evidence for a role of CTCF in AS. 
Binding of CTCF downstream of CD45 exon 5 leads to decel-
erating RNA Pol II elongation, thus permitting exon 5 inclu-
sion [20]. This mechanism is tightly regulated by cytosine 
methylation at CTCF binding sites in the DNA by the methyl-
cytosine dioxygenases TET1 and TET2 [21]. In another exam-
ple, CTCF binding to the BDNF2a locus was shown to be 
essential for its splicing by inhibiting TET1-induced DNA 
methylation and the subsequent interaction between TET1, 
MeCP2 and the splicing factor YB1 [22]. In contrast, DNA 
methylation at CTCF binding sites located upstream or 
downstream of alternatively spliced exons was associated 
with inclusion of exons [24]. Knowing that CTCF regulates 
DNA methylation and preserves methylation-free regions 
throughout the genome [50–52], we propose that CTCF reg-
ulates AS in a locus-dependent and tissue-specific manner.
CTCF has been recognised as a coordinator of chromatin 
looping and architecture [53–55]. Of immediate relevance is the 
observation that the RNA Pol II elongation rate can be con-
trolled by chromatin organisation and influence AS decisions 
[56,57]. A recent study showed that CTCF-mediated chromatin 
loops formed between promoters and intragenic regions, parti-
cularly at upstream sites of alternatively spliced exons, lead to 
exon inclusion [25]. However, this mechanism still requires 
further validation. Overall, these studies suggest a role for 
CTCF as a key modulator of splicing decisions at individual 
loci via different molecular and epigenetic mechanisms.
Given its global transcriptional regulation and insulation 
functions [6], altering CTCF expression could perturb var-
ious transcriptional signalling pathways and subsequently 
AS. In this context, reduced CTCF expression was found 
to be associated with increased exon exclusion, particularly 
in those exons located 1 kb upstream of CTCF binding sites 
in BL41 and BJAB B-lymphoma cells [20]. This suggests that 
reduction of CTCF expression and the distribution of CTCF 
binding sites can influence pre-mRNA processing decisions. 
Consistent with that, we showed that enrichment of Ctcf 
binding sites upstream and downstream of differentially 
retained introns in liver is associated with increased IR. 
From these results, we speculate that CTCF may regulate 
IR through modulating the RNA Pol II elongation rate and 
methylation status at CTCF target binding sites located 
proximal to differentially retained introns (Fig. 4B).
Our data support previous observations from our group and 
others that IR mostly affects introns which are short and GC- 
rich [36,38,58]. During granulocytic differentiation, some 
intron-retaining transcripts undergo NMD, triggered by pre-
mature termination codons located within the retained introns 
[36]. This process can lead to an overall reduction of gene 
expression consequent to IR. Here, we observed a net increase 
in gene expression in the liver of Ctcf+/- mice, suggesting an 
alternative predominant fate of intron-retaining transcripts.
We observed that there was an enrichment of genes related to 
RNA splicing and metabolism among the intron-retaining 
genes. Splicing factors affected by IR particularly in Ctcf+/- liver 
and kidney such as Srsf1, Esrp2 and Prpf40b have been previously 
reported to be associated with the regulation of AS including IR 
[35,59,60]. In addition to splicing, genes involved in metabolic 
processes were affected by IR in Ctcf haploinsufficient liver. We 
previously reported that Ctcf haploinsufficient mice exhibit 
~14% reduction in body weight during post-natal development 
[16]. Given that the liver plays an essential role in organismal 
metabolism, we propose that Ctcf-regulated IR in liver may 
affect metabolic genes and pathways that contribute to this 
body weight phenotype. Ctcf is a haploinsufficient tumour sup-
pressor that induces spontaneous tumour formation in various 
mouse tissues including liver [17]. The liver exhibited the most 
abundant IR events observed in our study. Given the fact that IR 
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is upregulated in most human cancers including liver cancer 
[45], a new link between CTCF haploinsufficiency and hepato-
cellular carcinoma causation via IR may be possible.
In this study, we have further defined the role of Ctcf in AS 
regulation and found Ctcf dosage-dependent effects on tissue- 
specific gene expression. Our analysis of Ctcf binding sites 
around retained introns in normal liver confirmed their rele-
vance especially in short and GC-rich introns. To gain 
a mechanistic understanding of tissue-specific IR in Ctcf hap-
loinsufficiency, additional studies are required that focus on 
Ctcf DNA occupancy and the interplay with the epigenetic 
regulation of AS. Moreover, causal links between Ctcf hap-
loinsufficiency, IR, and increased tumour formation should be 
further investigated.
Materials and methods
Mouse model, genotyping and organ collection
All mouse experiments were conducted in accordance with 
the New South Wales Animal Research Act 1985, and the 
Australian code for the care and use of animals for scientific 
purposes (8th edition 2013). Animal ethics approval for all 
mouse experiments was obtained from the Sydney Local 
Health District Animal Welfare Committee (Protocol number 
2016/020). C57BL/6J female mice from Australian 
BioResources, Australia were used as breeding stock. Ctcf+/− 
mice were originally obtained on a mixed C57BL/6:129SvJ 
background from the Fred Hutchinson Cancer Research 
Centre (Seattle, WA, USA) as a kind gift from Galina 
Filippova. These mice were previously backcrossed onto 
C57Bl/6J mice for at least 10 generations. Ctcf+/- mice contain 
a hemizygous deletion of the entire Ctcf coding region and 
substituted with an expression cassette containing the 3-phos-
phoglycerate kinase promoter and Neomycin gene flanked by 
two loxP sites (Pgk-Neo) [15,16]. Genotyping primers used to 
distinguish WT and Ctcf+/- alleles were Ctcf-WT-5ʹ 
(CTCACGCCTGAGATGATCC), Ctcf-WT-3ʹ (CATGCCATC 
CTACTGGTGTG) and Ctcf-neo-5ʹ (TGGGCTCTATGG 
CTTCTGAG). The resultant amplicons represent the WT 
allele (519 bp) and PGK-Neo-containing allele (348 bp).
Six healthy female C57BL/6 Ctcf+/+ and Ctcf+/- mice (3 
each) were utilised. At 11 weeks of age, two litters, one con-
taining 2xWT and 2xCtcf+/- female mice, the other containing 
one WT and one Ctcf+/- female mouse each were euthanised 
by carbon dioxide asphyxiation as recommended by the insti-
tutional animal welfare guidelines. Organs of interest (brain, 
kidney, liver, muscle and spleen) were collected and snap- 
frozen in liquid nitrogen, and stored at −80°C.
Protein extraction and quantitation
To extract protein from mouse organs, a small piece of the 
organ was minced in ice-cold RIPA protein lysis buffer 
(50 mM Tris-HCL (pH 8.0), 150 mM NaCl, 0.1% (w/v) 
sodium dodecyl sulphate (SDS), 0.5% (w/v) sodium deoxy-
cholate, 1% (v/v) NP-40 and 0.02% (w/v) sodium azide in 
distilled H2O with the addition of 1X EDTA-free 
SIGMAFAST protease cocktail tablet (Sigma). To quantify 
protein in the tissue lysates, the Micro BCA Protein Assay 
Kit (Thermo Fisher Scientific) was used according to the 
manufacturer’s protocol.
Western blot, antibodies and densitometry
For Western blot analysis, protein extracts were prepared as 
equal aliquots (10 μg) and boiled in 2X protein loading buffer 
containing NuPAGE LDS Sample Buffer and 100 mM 
Dithiothreitol (DTT) for 5 minutes. The samples were then 
resolved by 4–12% SDS-PAGE using NuPAGE Bis-Tris 
Protein Gel system (Thermo Fisher Scientific), and trans-
ferred onto a PVDF membrane (Merck Millipore) in a semi- 
dry transfer apparatus. Rabbit polyclonal anti-CTCF (1:2,000; 
#3418, Cell Signalling) or mouse monoclonal anti-GAPDH 
(1:5,000 dilution; ab8245; Abcam) was used as a primary anti-
body, followed by washing and staining with horseradish 
peroxidase-conjugated donkey anti-rabbit or anti-mouse IgG 
secondary antibodies (1:5,000 dilution; Merck Millipore), 
respectively. A Chemidoc Touch (BioRad) was used to visua-
lise the protein bands on these replicate blots, which were 
subjected to densitometric analysis using ImageJ software.
RNA isolation, purification and quantitation
To isolate RNA from WT and Ctcf+/- tissues of interest, a small 
piece of tissue (<30 mg weight) was homogenised with TRIzol 
reagent (Invitrogen) followed by isopropanol precipitation at 
−80°C. Next, contaminating DNA was eliminated by using the 
TURBO DNA-free kit (Invitrogen). The RNA quantitation and 
quality were assessed by NanoDrop 1000 Spectrophotometer 
(Thermo Fisher Scientific). Only samples with a 260/280 nm absor-
bance ratio of 1.9 or above were used. The RNA integrity was 
evaluated using a 2100 Bioanalyzer with the RNA 6000 Nano kit 
(Agilent) where samples with an RNA integrity number (RIN) 
below 7 were excluded.
RT-qPCR
To determine the relative expression level of Ctcf mRNA, 
cDNA was synthesised using SuperScript III Reverse 
Transcriptase (Invitrogen) followed by RNaseOUT treatment 
(Invitrogen). Next, qPCR was performed on the cDNA with 
SYBR Green (Bio-Rad) and Ctcf-specific forward 
(CCACCTGCCAAGAAGAGAAG) and reverse (CGACCTG 
AATGATGGCTGTT) primers, and subsequently run on 
a CFX96 real-time PCR machine (BioRad). Primers detecting 
Hprt were used to normalise gene expression: forward 
(AGTGTTGGATACAGGCCAGAC) and reverse (CGT 
GATTCAAATCCCTGAAGT). The fold-change was calcu-
lated using the 2–∆∆Ct method. The Ctcf mRNA expression 
levels in Ctcf+/- mouse tissues were normalised to WT to 
obtain the relative mRNA expression.
RNA sequencing
A total of 30 RNA samples (five tissues collected from three 
biological replicates each of WT and Ctcf+/- mice), which met 
the quality control parameters described above, were sent to 
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Novogene (Beijing, China) for library preparation (strand- 
specific, poly-A enriched) and RNA-seq (150 bp paired-end 
reads, over 100 million reads) using the Illumina HiSeq- 
PE150 platform.
Bioinformatic analysis
Initial quality control of the RNA-seq raw data was conducted 
using FastQC (bioinformatics.babraham.ac.uk/projects/fastqc) 
and MultiQC (multiqc.info) to check for sequencing quality 
prior to analysis [61]. After passing the quality control check, 
reads were mapped to the mouse reference genome GRCm38/ 
mm10 using STAR software [62]. To examine differential 
gene expression in WT and Ctcf+/- tissue samples, read counts 
were determined using featureCounts 1.5.0-p3 [63] and then 
subjected to differential gene expression analysis using the 
R Bioconductor package DESeq2 1.25.15 [64]. Genes with 
low read counts (<5) across all samples were removed. 
Differential AS was analysed using rMATS 4.0.1 [34], while 
further analysis of differential IR was performed using 
IRFinder 1.2.5 [35]. Specific IR features such as intron length 
and GC content were calculated using BEDTools v2.26.0 [65]. 
GO analysis of differentially expressed genes and intron- 
retaining genes were performed using the DAVID 6.8 online 
tool [66].
Validation of retained-intron candidates
Several candidates from the subset of intron-retaining tran-
scripts in Ctcf+/- liver were selected for validation by RT-qPCR 
according to stringent filtering parameters from the main 
IRFinder output file. These filtering parameters included 
mean IR-ratio ≥0.1, mean intron coverage >75%, mean intron 
depth ≥5 reads, mean splice junction depth ≥20 reads, and 
p-value of IR-ratio fold-change between WT and Ctcf+/- sam-
ples <0.05. Further details of these parameters are provided in 
the IRFinder manual (github.com/williamritchie/IRFinder/ 
wiki). Selected differentially retained introns were also visually 
inspected using the Integrative Genomics Viewer software 
(software.broadinstitute.org/software/igv/). On the other 
hand, expressed non-retained introns were selected for ana-
lyses based on the following criteria: (i) mean IR-ratio = 0 and 
(ii) mean splice junction depth >50 (as surrogate for 
expression).
Next, the selected candidates were validated by RT-qPCR 
using a set of three specific primers (Supplementary Table 5). 
To measure the relative mRNA expression, two primers were 
used to amplify sequence spanning the exonic region adjacent 
to the retained intron (Forward) to cross the exon-exon 
junction flanking the retained intron (Reverse 1). To measure 
the retained intron in the target spliced isoform, a third 
primer was designed to anneal within the intronic region of 
the retained intron (Reverse 2). Finally, the relative mRNA 
expression was calculated as described above while intron- 
retaining transcript expression was calculated after normal-
ising its expression to the expression of the intron’s flanking 
exons.
Enrichment of Ctcf binding sites
To examine enrichment of Ctcf binding sites, we obtained pub-
licly available ChIP-seq datasets from C57BL/6 normal mouse 
liver (E-MTAB-5769) [42] as well as brain, kidney, and spleen 
(GSE36027) [4]. We could not find ChIP-seq data from muscle. 
The Ctcf ChIP-seq peaks were then intersected with differen-
tially retained introns and expressed non-retained introns. To 
identify Ctcf binding sites, the FASTA sequences of the detected 
Ctcf peaks in the region located up to 3000 nt upstream of the 
differentially retained introns were first retrieved using 
BEDTools v2.26.0 [65]. Next, these sequences were scanned for 
the CTCF binding motif from JASPAR2020 database [67] using 
the FIMO program from the MEME suite v.4.12.0 [68,69].
Statistical analysis
The data from this study was analysed using different statistical 
tests relevant to the type of experiment or analysis. Wald test 
and unpaired two-tailed Student’s t-test (as indicated in Figure 
legends) were used to determine statistical significance. P-values 
<0.05 were considered as statistically significant. All error bars 
shown in the figures represent standard error of the mean 
(SEM) from at least three independent experiments. The 
GraphPad Prism software version 7 as well as R Bioconductor 
were used to perform the statistical data analyses.
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